Cancer play Syndax files for IPO

Syndax Pharmaceuticals Inc. (Waltham, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Deutsche Bank; Jefferies; JMP Securities; and Wedbush PacGrow. Next month, the ECOG-ACRIN Cancer Research Group plans to start a Phase III trial to evaluate Syndax's entinostat ( SNDX-275) to treat estrogen receptor-positive breast cancer in postmenopausal women who have progressed on an aromatase inhibitor. NIH's National Cancer Institute (NCI) is sponsoring the trial, which has an SPA from FDA. ...